On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.
Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."
Data provided by Nasdaq. Minimum 15 minutes delayed.
March 07, 2017
Nuvectra™ Reports Fourth Quarter and Full Year 2016 Financial Results
PLANO, Texas, March 07, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 30, 2016. Recent Highlights Completed FDA Premarket Approval and TUV CE mark submissions for Virtis™ Executed direct supply agreement with Minnetronix for Algovita® external devices Extended availability of the final two tranches of the $45 million debt facility U.S.
March 06, 2017
Nuvectra to Present at the 29th Annual ROTH Conference
PLANO, Texas, March 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th Annual ROTH Conference in Dana Point, CA. Management will also be available for one-on-one meetings at the conference. Event: 29th Annual ROTH Conference Date: Monday, March 13, 2017 Time: 1:0
The Ruth Group
|There are currently no events scheduled.|